Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2024

Open Access 01-12-2024 | Cardiac Amyloidosis | Research

Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Background

Cardiac involvement in patients with immunoglubin light-chain amyloidosis (AL) is a major determinant of treatment choice and prognosis, and early identification of high-risk patients can initiate intensive treatment strategies to achieve better survival. This study aimed to investigate the prognostic value of native T1 and ECV in patients with AL-cardiac amyloidosis (CA).

Methods

A total of 38 patients (mean age 59 ± 11 years) with AL diagnosed histopathologically from July 2017 to October 2021 were collected consecutively. All patients were performed 3.0-T cardiac magnetic resonance (CMR) including cine, T1 mapping, and late gadolinium enhancement (LGE). Pre- and post-contrast T1 mapping images were transferred to a dedicated research software package (CVI42 v5.11.3) to create parametric T1 and ECV values. In addition, clinical and laboratory data of all patients were collected, and patients or their family members were regularly followed up by telephone every 3 months. The starting point of follow-up was the time of definitive pathological diagnosis, and the main endpoint was all-cause death. Kaplan-Meier analysis and Cox proportional risk model were used to evaluate the association between native T1 and ECV and death in patients with CA.

Results

After a median follow-up of 27 (16, 37) months, 12 patients with CA died. Kaplan-Meier analysis showed that elevated native T1 and ECV were closely associated with poor prognosis in patients with CA. The survival rate of patients with ECV > 44% and native T1 > 1389ms were significantly lower than that of patients with ECV ≤ 44% and native T1 ≤ 1389ms (Log-rank P < 0.001), and was not associated with the presence of LGE. After adjusting for clinical risk factors and CMR measurements in a stepwise multivariate Cox regression model, ECV [risk ratio (HR):1.37, 95%CI: 1.09–1.73, P = 0.008] and native T1 (HR:1.01, 95%CI: 1.00-1.02, P = 0.037) remained independent predictors of all-cause mortality in patients with CA.

Conclusions

Both native T1 and ECV were independently prognostic for mortality in patients with CA, and can be used as important indicators for clinical prognosis assessment of AL.
Literature
2.
go back to reference Bellavia D, Pellikka PA, Al-Zahrani GB, et al. Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort Study. J Am Soc Echocardiogr. 2010;23(6):643–52.CrossRefPubMedPubMedCentral Bellavia D, Pellikka PA, Al-Zahrani GB, et al. Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort Study. J Am Soc Echocardiogr. 2010;23(6):643–52.CrossRefPubMedPubMedCentral
3.
go back to reference Adam RD, Coriu D, Jercan A, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021;8(4):2380–96.CrossRefPubMedPubMedCentral Adam RD, Coriu D, Jercan A, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021;8(4):2380–96.CrossRefPubMedPubMedCentral
4.
go back to reference Patel RK, Fontana M, Ruberg FL. Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging. 2021;14(6):e009025.CrossRefPubMedPubMedCentral Patel RK, Fontana M, Ruberg FL. Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging. 2021;14(6):e009025.CrossRefPubMedPubMedCentral
5.
go back to reference Cooper LT, Baughman KL, Feldman AM, American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.CrossRefPubMed Cooper LT, Baughman KL, Feldman AM, American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.CrossRefPubMed
6.
go back to reference Koyama J, Falk RH. Prognostic significance of strain doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3:333–42.CrossRefPubMed Koyama J, Falk RH. Prognostic significance of strain doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3:333–42.CrossRefPubMed
7.
go back to reference Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–81.CrossRefPubMed Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477–81.CrossRefPubMed
8.
go back to reference Cyrille NB, Goldsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089–93.CrossRefPubMed Cyrille NB, Goldsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089–93.CrossRefPubMed
9.
go back to reference Vidal-Perez R, Vázquez-García R, Barge-Caballero G, et al. Diagnostic and prognostic value of cardiac imaging in amyloidosis. World J Cardiol. 2020;12(12):599–614.CrossRefPubMedPubMedCentral Vidal-Perez R, Vázquez-García R, Barge-Caballero G, et al. Diagnostic and prognostic value of cardiac imaging in amyloidosis. World J Cardiol. 2020;12(12):599–614.CrossRefPubMedPubMedCentral
10.
go back to reference Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–9.CrossRefPubMed Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–9.CrossRefPubMed
11.
go back to reference Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.CrossRefPubMed Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.CrossRefPubMed
12.
go back to reference Yumeng L, Jingfen Z, Meng C, et al. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis. Ann Transl Med. 2022;10(14):794.CrossRef Yumeng L, Jingfen Z, Meng C, et al. 3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis. Ann Transl Med. 2022;10(14):794.CrossRef
13.
go back to reference Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic lightchain amyloidosis. Leukemia. 2012;26(11):2317–25.CrossRefPubMed Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic lightchain amyloidosis. Leukemia. 2012;26(11):2317–25.CrossRefPubMed
14.
go back to reference Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.CrossRefPubMedPubMedCentral Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.CrossRefPubMedPubMedCentral
15.
go back to reference Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–68.CrossRefPubMedPubMedCentral Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–68.CrossRefPubMedPubMedCentral
16.
go back to reference Kim D, Choi JO, Kim K et al. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail. 2020;(4). Kim D, Choi JO, Kim K et al. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail. 2020;(4).
17.
go back to reference Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.CrossRefPubMed Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.CrossRefPubMed
18.
go back to reference Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787–9.CrossRefPubMed Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787–9.CrossRefPubMed
19.
go back to reference Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.CrossRefPubMed Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.CrossRefPubMed
20.
go back to reference Wong SW, Hegenbart U, Palladini G, et al. Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018;18(11):e493–9.CrossRefPubMedPubMedCentral Wong SW, Hegenbart U, Palladini G, et al. Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018;18(11):e493–9.CrossRefPubMedPubMedCentral
21.
go back to reference Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.CrossRefPubMed Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.CrossRefPubMed
22.
go back to reference Boynton SJ, Geske JB, Dispenzieri A, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.CrossRefPubMed Boynton SJ, Geske JB, Dispenzieri A, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.CrossRefPubMed
23.
go back to reference Hotta VT, Giorgi MCP, Fernandes F, et al. Cardiac amyloidosis: non-invasive diagnosis. Rev Assoc Médica Bras. 2020;66(3):345–52.CrossRef Hotta VT, Giorgi MCP, Fernandes F, et al. Cardiac amyloidosis: non-invasive diagnosis. Rev Assoc Médica Bras. 2020;66(3):345–52.CrossRef
24.
go back to reference Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9.CrossRefPubMedPubMedCentral Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9.CrossRefPubMedPubMedCentral
25.
go back to reference Agha AM, Palaskas N, Patel AR, et al. Cardiac magnetic resonance predicting outcomes among patients at risk for cardiac AL amyloidosis. Front Cardiovasc Med. 2021;8:626414.CrossRefPubMedPubMedCentral Agha AM, Palaskas N, Patel AR, et al. Cardiac magnetic resonance predicting outcomes among patients at risk for cardiac AL amyloidosis. Front Cardiovasc Med. 2021;8:626414.CrossRefPubMedPubMedCentral
26.
go back to reference Lin L, Li X, Feng J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson. 2018;20(1):2.CrossRefPubMedPubMedCentral Lin L, Li X, Feng J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson. 2018;20(1):2.CrossRefPubMedPubMedCentral
28.
go back to reference Weingärtner S, Meßner NM, Budjan J, et al. Myocardial T1-mapping at 3T using saturation-recovery: reference values, precision and comparison with MOLLI. J Cardiovasc Magn Reson. 2016;18(1):84.CrossRefPubMedPubMedCentral Weingärtner S, Meßner NM, Budjan J, et al. Myocardial T1-mapping at 3T using saturation-recovery: reference values, precision and comparison with MOLLI. J Cardiovasc Magn Reson. 2016;18(1):84.CrossRefPubMedPubMedCentral
29.
go back to reference Piechnik SK, Ferreira VM, Lewandowski AJ, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5T using ShMOLLI. J Cardiovasc Magn Reson. 2013;15:13.CrossRefPubMedPubMedCentral Piechnik SK, Ferreira VM, Lewandowski AJ, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5T using ShMOLLI. J Cardiovasc Magn Reson. 2013;15:13.CrossRefPubMedPubMedCentral
30.
go back to reference Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818–29.CrossRefPubMed Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818–29.CrossRefPubMed
31.
go back to reference Ritts AJ, Cornell RF, Swiger K, et al. Current concepts of cardiac amyloidosis. Heart Fail Clin. 2017;13(2):409–16.CrossRefPubMed Ritts AJ, Cornell RF, Swiger K, et al. Current concepts of cardiac amyloidosis. Heart Fail Clin. 2017;13(2):409–16.CrossRefPubMed
Metadata
Title
Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis
Publication date
01-12-2024
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-03756-8

Other articles of this Issue 1/2024

BMC Cardiovascular Disorders 1/2024 Go to the issue